The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
contd
?Stem cells are developing mesenchymal stem cells with excellent immunomodulacyte function as a treatment primarily targeting immune diseases. Domestic companies include Daewoong Pharma, MediPost, Green Cross Lab Cell, Gangstem Biotech, SCM Life Sciences, and Cha Biotech. Recently, the development of therapeutic agents using 'CAR-Treg' introducing the CAR gene to regulated T cells in the field of immunodefiguration is also underway, and representative companies include Sangamo (Sangamo) and TeraImmune.
- Explain the status of pipeline development.
?The first pipeline (AFX001) is developing a treatment for organ transplant rejection reactions and graft-based housing diseases. We confirmed the final excellent medicinal agent apimer, which can exhibit antagonism for rats and human target proteins, and introduced it into DW-MSC to build apicell cell lines. In vivo (in vivo) efficacy evaluation of the established cell line is speeding up sample production and related R&D in order to begin the evaluation of the efficacy. In 2023, he will complete a preclinical award and apply for ind for clinical phase 1 in the second half of that year. The goal is to sign a license-out agreement before clinical phase 1 of the AFX001 is completed.
-In February of this year , series A funding was completed
. I think it's a good thing that we've created a solid foundation for technology development, and we've recognized the technical value of the Apicell platform, which seeks to raise corporate value and complete future developments.
Series B is preparing to open from the end of this year and finish in the first half of next year. It will be used for clinical entry of the first project and expansion of the pipeline. It also plans to attract overseas strategic investors (SI) who can cover value chains.
- If you introduce the equity ratio of major shareholders and financial investors (FI).
?Daewoong Pharma and Abakta, the parent company, hold about 63% of the total shares. Fi includes Shinhan Venture Investment, Smilegate Investments, Shinhan Financial Investments, Samsung Venture Investments, Stonebridge Ventures, Kolon Investments, and Gyeongnam Venture Investments.
- If you're planning an IPO, that's the point.
?In the second half of 2025, kosdaq market listing is aimed at listing. 2025 is also the time of the IPO, when we can prove the differentiated strengths of the Apicell platform by conducting clinical phase 1 and phase 2 of AFX001's organ transplant rejection response and graft-based home disease treatment. Clinical phase 1 of the AFX002 platform is also expected to take place. We plan to continue to increase our corporate value after the IPO for various pipeline clinical trials and expansions "
Few translation letters errors but gives a good picture of the future potential .
"DAEWOONG PHARMA'S APISEL TERRAFUTICS CHALLENGES SERIES B NEXT YEAR
? ABAKTA AND JOINT CELL GENES TREATMENT COMPANY... YOO JONG-SANG, CEO, "IPO GOALS FOR 2025"
ia kyung journalist | public 2021-10-22 08:22:54
this article was shown on the dorbel toll page on october 21, 2021 at 16:16.
Daewoong Pharma's new drug development strategy is an open collaboration. It is a strategy to develop technology within the company using external knowledge and technology. Apisel Terrafutics is a representative achievement of open collaboration. Yoo Jong-sang (CSO), who is from Daewoong Pharmaceutical Cell Therapy Center, leads the company with Jeon Seung-ho.
ApiselTeraFutics was co-founded by Daewoong Pharma and British biotech Avacta. Daewoong Pharma's mesenchymal stem cell mass production technology and Abacta's antibody-fluid protein 'Apimer' technology are combined to develop a new non-antibody protein-type therapeutic agent. In the first half of next year, series B funding will speed up R&D and then go to an IPO in 2025. The following is a question and answer from Yoo Jong-sang.
-To briefly introduce Apicell Therapy, ?Apicell Therapy is a next-generation cell gene therapeutics development company. Based on Daewoong Pharma's mesenchymal stem cell platform 'DW-MSC' technology, it develops 'AffyXell', which fuses Abakta's Affimer platform technology, a type of non-immunity Globlin scaffold protein, to enhance immunomodulatory function.
Both technologies have overcome existing limitations. 'DW-MSC' has overcome the short lifespan and productivity limits of existing adult tissue-derived mesenchymal stem cells, and 'apimer' acts like an antibody, but the price is low and the size is small, which has an advantage in tissue burden. The goal is to develop an immune and inflammation-related disease treatment with a clear mechanism of action with the synergy of dw-MSC's immunomodulation function and the target active control function of the appetizer.
-The meaning (background) of the company's name is ?AffyXell is the name of the company and the name of the therapeutic platform to develop. The word Affy means "trust, engagement", which means fusion. X represents the chromosomes in our body and means the development of new cells through severe genetic modification. By using X instead of C in Cell, we are willing to introduce genes of specific functions to create new cell therapies that have never been before.
- If you have a company with the nearest business model.
Some Excellent Partners and Investors
https://affyxell-com.translate.goog/media/partner.php?PHPSESSID=0aa564a4eb585fbfb33d6833f5c34d7f&_x_tr_sl=auto&_x_tr_tl=en&_x_tr_hl=en-GB&_x_tr_pto=wapp&_x_tr_sch=http
Richob,
Good find. Worth repeating the quote from your link:
“The US is a very important and large market for us and in order to exploit the scale of the opportunity in North America effectively, we have decided to establish a presence on both the east and west coasts. This expansion is a strong signal of our confidence in the technology and the growing interest from pharma, biotech and diagnostics that is being driven by the new data and applications that is rapidly emerging from our own and collaborators’ laboratories. "
STRONG SIGNAL OF OUR CONFIDENCE AND GROWING INTEREST FROM PHARMA- What' not to like?
Thanks all for finding, translating and sharing!
Really nice to see that Avacta and Daewoong still own 63% of AffyXell at this stage. This is what I was looking for after the series A funding, but could not find at the time.
It’s not clear still what the split is with Daewoong, but assuming Avacta have c.30% of AffyXell, it’s still a decent chunk of a very exciting business that sounds like it’s making good progress already.
Informative research thanks everyone for taking the time to share .
https://twitter.com/lee_williams97/status/1486266959369023490
Just looked - you are right but also they are much closer to market. Substantially higher again than affyxell. Makes me think Avacta with all its various projects is the gift that could keep on giving. Chemo, followed by immunology followed by stem cells over the next 10 years
Re atarabio...their market cap is some 4x that of avacta. Just for info.
The Koreans are thinking long term and so should we...thanks guys for the info/translations...
Is this him?
https://www.labmate-online.com/news/news-and-views/5/avacta-group/avacta-expands-development-team-in-us/44441
Onwards Avacta
May or may not need updating ?
POINT Biopharma Adds Senior BD Expertise with Appointment of Dr. Matthew Vincent as SVP, Business Development
Yes seems to be working
Korean website was working just now
http://affyxell.com/company/intro.php?s=09
AS and Matt Vincent on Board of Directors.
Muck thank you for all your hard work - real achievement.
Looks like they will be competing in similar space to
https://www.atarabio.com/
They are more advanced but posting website cause it gives good idea on timelines etc
Part 2
?First of all, attracting 8 billion won in Series A investment is the biggest achievement this year. It laid a solid foundation for technology development, and I think it is meaningful that the technological value of the Apicell platform, which aims to enhance corporate value and complete future development, was recognized.
Series B is expected to open at the end of this year and be completed within the first half of next year. It will be used for clinical entry and pipeline expansion of the first project. It also plans to attract overseas strategic investors (SIs) who can cover the value chain.
-If you introduce the equity ratio of major shareholders and financial investors (FIs).
?The parent companies Daewoong Pharmaceutical and Avacta hold about 63% of the total stock. FIs include Shinhan Venture Investment, Smilegate Investment, Shinhan Financial Investment, Samsung Venture Investment, Stone Bridge Ventures, Kolon Investment, and Gyeongnam Venture Investment.
? The goal is to be listed on the KOSDAQ market in the second half of 2025. 2025 is not only the time of IPO, but also the time to prove the differentiated strength of the Apicel platform by conducting phase 1 and 2 clinical trials for AFX001's organ transplant rejection and graft-versus-host disease treatment. Phase 1 clinical trials of the AFX002 platform are also expected to proceed. The company plans to continuously increase its corporate value after the IPO for various pipeline clinical trials and expansion.
Managed to get into the site - this Q&A with the CEO is worth a read (forgive the spelling errors post translation!
Part 1
“?AffyXell is the name of the company as well as the name of the treatment platform to be developed. The word Affy means 'trust, betrothed' and broadly means fusion. X represents the chromosomes in our body and means the development of new cells through genetic modification. By using X instead of C in Cell, it contains the will to create a new cell therapy product that has never been before by introducing a gene with a specific function.“
“? Stem cells are developing mesenchymal stem cells, which have excellent immunomodulatory functions, as therapeutic agents that mainly target immune diseases. Domestic related companies include Daewoong Pharmaceutical, Medipost, Green Cross Lab Cell, Kang Stem Biotech, SCM Life Sciences, and CHA Biotech. Recently, in the field of immune diseases, the development of therapeutics using 'CAR-Treg', which introduces a CAR gene into regulatory T cells, is also in progress.“
“?The first pipeline (AFX001) is developing a treatment for organ transplant rejection and graft-versus-host disease. We confirmed the final excellent drug apimer capable of exhibiting antagonistic action against mouse and human target proteins, and introduced it into DW-MSC to construct the apicell cell line. We are accelerating the production of samples and related R&D in order to start the evaluation of efficacy in in vivo experiments on the established cell lines within this year. It plans to complete preclinical trials in 2023 and apply for IND for phase 1 clinical trials in the second half of that year. It is also aiming to conclude a license out contract before the phase 1 clinical trial of AFX001 is completed.”
I managed to look at a snapshot of the site as at 7/12/21 using the the wayback machine (web.archive.org). It’s painfully slow and then you have to use google translate. Various bits and pieces, with 2 pipeline therapeutics, AFX001 and AFX002.
AFX001
Stage : Discovery
Cell type : Engineered MSC
MoA : Suppression of T-cell mediated B-cell activation
Target : undisclosed
Dose Route : Intravenous Injection
Pre-clinical stage will begin in 2022
AFX002
Stage : Discovery
Cell type : Engineered MSC
MoA : Inhibition of T-cell proliferation & cytokine production
Target : undisclosed
Dose Route : Intravenous Injection
Pre-clinical stage will begin in end of 2022
worked ok for me around 30 mins ago, but blocked now.
gmcc....are you using a VPN?
I'm blocked too.
Sorry neither links work for me, just blocked/ no entry!
Thanks Poirot. Website working http://affyxell.com/
Mention of this company " apisel terrafutics co., ltd." ?
Good find. Thank you for posting. The various bits of jigsaw for the JV are better than the sum of the parts and your find is j one piece (great piece) but highlights all the others. Effectively Avacta life so many of their partnerships have a free ride - limited risk, limited resources and a revenue stream in making. We might hear more regular updates as all these projects enter various clinical and commercial milestones.
In meantime avacta can focus on their own Tx projects all funded by above milestones, nasfaq listing or LFD
Oh hang on....
Energy,
sounds reasonable!